Literature DB >> 21326832

The Bacterial Ghost platform system: production and applications.

Timo Langemann1, Verena Juliana Koller, Abbas Muhammad, Pavol Kudela, Ulrike Beate Mayr, Werner Lubitz.   

Abstract

The Bacterial Ghost (BG) platform technology is an innovative system for vaccine, drug or active substance delivery and for technical applications in white biotechnology. BGs are cell envelopes derived from Gram-negative bacteria. BGs are devoid of all cytoplasmic content but have a preserved cellular morphology including all cell surface structures. Using BGs as delivery vehicles for subunit or DNA-vaccines the particle structure and surface properties of BGs are targeting the carrier itself to primary antigen-presenting cells. Furthermore, BGs exhibit intrinsic adjuvant properties and trigger an enhanced humoral and cellular immune response to the target antigen. Multiple antigens of the native BG envelope and recombinant protein or DNA antigens can be combined in a single type of BG. Antigens can be presented on the inner or outer membrane of the BG as well as in the periplasm that is sealed during BG formation. Drugs or supplements can also be loaded to the internal lumen or periplasmic space of the carrier. BGs are produced by batch fermentation with subsequent product recovery and purification via tangential flow filtration. For safety reasons all residual bacterial DNA is inactivated during the BG production process by the use of staphylococcal nuclease A and/or the treatment with β-propiolactone. After purification BGs can be stored long-term at ambient room temperature as lyophilized product. The production cycle from the inoculation of the pre-culture to the purified BG concentrate ready for lyophilization does not take longer than a day and thus meets modern criteria of rapid vaccine production rather than keeping large stocks of vaccines. The broad spectrum of possible applications in combination with the comparably low production costs make the BG platform technology a safe and sophisticated product for the targeted delivery of vaccines and active agents as well as carrier of immobilized enzymes for applications in white biotechnology.
© 2010 Landes Bioscience

Entities:  

Keywords:  E-mediated lysis; bacterial ghosts; bacterial inactivation; drug carrier; fermentation; tumor treatment; vaccines; white biotechnology

Mesh:

Substances:

Year:  2010        PMID: 21326832      PMCID: PMC3037582          DOI: 10.4161/bbug.1.5.12540

Source DB:  PubMed          Journal:  Bioeng Bugs        ISSN: 1949-1018


  84 in total

1.  Genetic evidence that the bacteriophage phi X174 lysis protein inhibits cell wall synthesis.

Authors:  T G Bernhardt; W D Roof; R Young
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

Review 2.  Bacterial ghosts as carrier and targeting systems.

Authors:  W Lubitz
Journal:  Expert Opin Biol Ther       Date:  2001-09       Impact factor: 4.388

3.  Green fluorescent protein (GFP)-dependent separation of bacterial ghosts from intact cells by FACS.

Authors:  W Haidinger; M P Szostak; W Beisker; W Lubitz
Journal:  Cytometry       Date:  2001-06-01

Review 4.  Use of live bacterial vaccine vectors for antigen delivery: potential and limitations.

Authors:  E Medina; C A Guzmán
Journal:  Vaccine       Date:  2001-02-08       Impact factor: 3.641

5.  Surface-accessible residues in the monomeric and assembled forms of a bacterial surface layer protein.

Authors:  S Howorka; M Sára; Y Wang; B Kuen; U B Sleytr; W Lubitz; H Bayley
Journal:  J Biol Chem       Date:  2000-12-01       Impact factor: 5.157

6.  Intramuscular immunization with genetically inactivated (ghosts) Actinobacillus pleuropneumoniae serotype 9 protects pigs against homologous aerosol challenge and prevents carrier state.

Authors:  A Hensel; V Huter; A Katinger; P Raza; C Strnistschie; U Roesler; E Brand; W Lubitz
Journal:  Vaccine       Date:  2000-07-01       Impact factor: 3.641

Review 7.  Advances in specific immunotherapy of malignant melanoma.

Authors:  C Curiel-Lewandrowski; M F Demierre
Journal:  J Am Acad Dermatol       Date:  2000-08       Impact factor: 11.527

8.  Recombinant attenuated bacteria for the delivery of subunit vaccines.

Authors:  I Gentschev; G Dietrich; S Spreng; A Kolb-Mäurer; V Brinkmann; L Grode; J Hess; S H Kaufmann; W Goebel
Journal:  Vaccine       Date:  2001-03-21       Impact factor: 3.641

9.  Physical properties and in vitro transfection efficiency of gene delivery vectors based on complexes of DNA with synthetic polycations.

Authors:  Tomás Reschel; Cestmír Konák; David Oupický; Leonard W Seymour; Karel Ulbrich
Journal:  J Control Release       Date:  2002-05-17       Impact factor: 9.776

10.  Improved protection against lung colonization by Actinobacillus pleuropneumoniae ghosts: characterization of a genetically inactivated vaccine.

Authors:  V Huter; A Hensel; E Brand; W Lubitz
Journal:  J Biotechnol       Date:  2000-09-29       Impact factor: 3.307

View more
  52 in total

1.  Autotransporter-based antigen display in bacterial ghosts.

Authors:  Anna Hjelm; Bill Söderström; David Vikström; Wouter S P Jong; Joen Luirink; Jan-Willem de Gier
Journal:  Appl Environ Microbiol       Date:  2014-11-14       Impact factor: 4.792

2.  A novel inducible expression system for the functional study of toxic gene in bacteria.

Authors:  Jihua Guo; Rong Jia
Journal:  World J Microbiol Biotechnol       Date:  2013-12-11       Impact factor: 3.312

3.  Protective efficacy of a Salmonella Typhimurium ghost vaccine candidate constructed with a recombinant lysozyme-PMAP36 fusion protein in a murine model.

Authors:  Ja Young Moon; So Young Kim; Won Kyong Kim; Zhili Rao; Jung Hee Park; Ji Young Mun; Boram Kim; Hyo Sun Choi; Jin Hur
Journal:  Can J Vet Res       Date:  2017-10       Impact factor: 1.310

4.  Pharmacokinetics and risk evaluation of DNA vaccine against Schistosoma japonicum.

Authors:  Hai-Feng Liu; Wei Li; Ming-Bo Lu; Long-Jiang Yu
Journal:  Parasitol Res       Date:  2012-09-19       Impact factor: 2.289

Review 5.  Genital Chlamydia trachomatis: understanding the roles of innate and adaptive immunity in vaccine research.

Authors:  Sam Vasilevsky; Gilbert Greub; Denise Nardelli-Haefliger; David Baud
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

Review 6.  Potent and tumor specific: arming bacteria with therapeutic proteins.

Authors:  Nele Van Dessel; Charles A Swofford; Neil S Forbes
Journal:  Ther Deliv       Date:  2015-03

Review 7.  Bacterial components as naturally inspired nano-carriers for drug/gene delivery and immunization: Set the bugs to work?

Authors:  Fatemeh Farjadian; Mohsen Moghoofei; Soroush Mirkiani; Amir Ghasemi; Navid Rabiee; Shima Hadifar; Ali Beyzavi; Mahdi Karimi; Michael R Hamblin
Journal:  Biotechnol Adv       Date:  2018-02-28       Impact factor: 14.227

8.  Generation of a Novel Staphylococcus aureus Ghost Vaccine and Examination of Its Immunogenicity against Virulent Challenge in Rats.

Authors:  Nagarajan Vinod; Sung Oh; Hyun Jung Park; Jung Mo Koo; Chang Won Choi; Sei Chang Kim
Journal:  Infect Immun       Date:  2015-05-11       Impact factor: 3.441

9.  Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis.

Authors:  Diana Groza; Sebastian Gehrig; Pavol Kudela; Martin Holcmann; Christine Pirker; Carina Dinhof; Hemma H Schueffl; Marek Sramko; Julia Hoebart; Fatih Alioglu; Michael Grusch; Manfred Ogris; Werner Lubitz; Bernhard K Keppler; Irena Pashkunova-Martic; Christian R Kowol; Maria Sibilia; Walter Berger; Petra Heffeter
Journal:  Oncoimmunology       Date:  2018-02-16       Impact factor: 8.110

Review 10.  Recent trends and advances in microbe-based drug delivery systems.

Authors:  Pravin Shende; Vasavi Basarkar
Journal:  Daru       Date:  2019-08-02       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.